207 related articles for article (PubMed ID: 31068511)
21. Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor.
Shi PA; Miller LK; Isola LM
Transfusion; 2014 May; 54(5):1263-8. PubMed ID: 24128272
[TBL] [Abstract][Full Text] [Related]
22. Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.
Choi HY; Yong CS; Yoo BK
Ann Pharmacother; 2010 Jan; 44(1):117-26. PubMed ID: 20009003
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Veltri L; Cumpston A; Shillingburg A; Wen S; Luo J; Leadmon S; Watkins K; Craig M; Hamadani M; Kanate AS
Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754
[TBL] [Abstract][Full Text] [Related]
24. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
Attolico I; Pavone V; Ostuni A; Rossini B; Musso M; Crescimanno A; Martino M; Iacopino P; Milone G; Tedeschi P; Coluzzi S; Nuccorini R; Pascale S; Di Nardo E; Olivieri A
Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194
[TBL] [Abstract][Full Text] [Related]
25. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
26. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
[TBL] [Abstract][Full Text] [Related]
27. [Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell].
Ruano Camps R; Ortiz Pareja M; Vidales Mancha I; Muñoz Castillo IM; Heiniger Mazo AI
Farm Hosp; 2013; 37(4):317-21. PubMed ID: 24010693
[TBL] [Abstract][Full Text] [Related]
28. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
[TBL] [Abstract][Full Text] [Related]
29. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Malard F; Kröger N; Gabriel IH; Hübel K; Apperley JF; Basak GW; Douglas KW; Geraldes C; Jaksic O; Koristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF
Biol Blood Marrow Transplant; 2012 Feb; 18(2):314-7. PubMed ID: 22001752
[TBL] [Abstract][Full Text] [Related]
30. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
[TBL] [Abstract][Full Text] [Related]
31. Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.
Alsaeed AS; Najib MJ; Al Amoudi SM; Elhemaidi IY; Absi AA; Al Ahmadi MD; Eldadah SK; Rajkhan WA; Khalil MM; Almohammadi MH
Saudi Med J; 2022 Jun; 43(6):626-632. PubMed ID: 35675941
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
Micallef IN; Sinha S; Gastineau DA; Wolf R; Inwards DJ; Gertz MA; Hayman SR; Hogan WJ; Johnston PB; Lacy MQ; Ansell SM; Buadi F; Dingli D; Dispenzieri A; Litzow MR; Porrata LF; Winters JL; Kumar S
Biol Blood Marrow Transplant; 2013 Jan; 19(1):87-93. PubMed ID: 22922211
[TBL] [Abstract][Full Text] [Related]
33. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.
Lee SY; Sanchorawala V; Seldin DC; Mark Sloan J; Andrea N; Quillen K
Amyloid; 2014 Sep; 21(3):149-53. PubMed ID: 24779777
[TBL] [Abstract][Full Text] [Related]
34. Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.
Zhu J; Huang H; Chen H; Zhang X; Li Z; Wu D; Zhou D; Song Y; Hu Y; Liang Y; Ren H; Huang H; Li N; Chen H; Hu J; Li J; Meng R; Wu J; Yu D; Huang X
Transfusion; 2018 Jan; 58(1):81-87. PubMed ID: 29238988
[TBL] [Abstract][Full Text] [Related]
35. Autologous Stem Cell Mobilization in the Age of Plerixafor.
Cooper DL; Medoff E; Patel N; Baker J; Pratt K; Foss F; Seropian SE; Perreault S; Wu Y
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):411-6. PubMed ID: 27245311
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor.
Bilgin YM; Visser O; Beckers EA; te Boome LC; Huisman C; Ypma PF; Croockewit AJ; Netelenbos T; Kramer EP; de Greef GE
Transfusion; 2015 May; 55(5):1021-7. PubMed ID: 25641128
[TBL] [Abstract][Full Text] [Related]
37. Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience.
Malinowska I; Romiszewski M; Smalisz K; Stelmaszczyk-Emmel A; Nasilowska-Adamska B; Krol M; Urbanowska E; Brozyna A; Baginska-Dembowska B
Transfus Apher Sci; 2021 Jun; 60(3):103077. PubMed ID: 33583716
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
[TBL] [Abstract][Full Text] [Related]
39. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P
J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277
[TBL] [Abstract][Full Text] [Related]
40. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.
Lefrère F; Mauge L; Réa D; Ribeil JA; Dal Cortivo L; Brignier AC; Aoun C; Larghéro J; Cavazzana-Calvo M; Micléa JM
Transfusion; 2013 Mar; 53(3):564-9. PubMed ID: 22725259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
